- Merck & Co. partners with N-Power Medicine to improve access to cancer research studies.
- N-Power Medicine will deploy its real-time registry and AI platform to streamline oncology trial processes.
- The collaboration aims to foster innovation in cancer care by simplifying trial enrollment and data management.
- Merck’s motivation stems from N-Power’s novel approach to expanding clinical research capabilities.
- N-Power recently completed a $72 million funding round led by Merck’s Global Health Innovation Fund.
Main AI News:
Merck & Co. has announced a strategic collaboration with N-Power Medicine, a trials tech firm based in Redwood City, California, to revolutionize access to cancer research studies. The financial terms of the partnership were not disclosed.
Under this agreement, N-Power Medicine will leverage its advanced real-time registry and point-of-care platform to facilitate broader participation of oncologists and their patients in clinical research. This initiative aims to accelerate innovation within the cancer care ecosystem by simplifying the complexities associated with trial enrollment and patient management.
Marjorie Green, Head of Oncology Clinical Development at Merck, highlighted N-Power’s innovative approach to expanding clinical research as a key motivation for the collaboration. She emphasized that this partnership presents a significant opportunity to drive essential advancements in cancer care.
N-Power Medicine, led by CEO Mark Lee, focuses on partnering with oncology clinics to introduce a reinvented framework and necessary resources for expanding access to clinical trials. The company’s AI-powered technologies include a comprehensive clinical trial suite that facilitates patient recruitment, analytics, and support services. Additionally, their data generation suite enhances data collection and quality management processes.
A notable component of N-Power’s technology is the real-time Kaleido Registry, which utilizes AI to streamline the collection of standardized patient data. This approach aims to optimize trial recruitment and enrollment processes, ultimately improving the efficiency and effectiveness of clinical research efforts.
The partnership with Merck follows N-Power’s successful completion of a $72 million Series B funding round, with significant backing from the Merck Global Health Innovation Fund. This funding will support N-Power’s expansion efforts, including the growth of their network of oncology clinics and collaborations with biopharmaceutical companies.
This collaboration underscores Merck’s commitment to advancing cancer treatment through innovative technologies and strategic partnerships. N-Power Medicine, bolstered by strong financial support and a robust technological framework, is poised to play a pivotal role in reshaping the landscape of cancer clinical trials with its AI-driven solutions.
Conclusion:
The partnership between Merck & Co. and N-Power Medicine marks a significant advancement in the oncology clinical trial landscape. By leveraging AI-powered solutions to streamline patient data management and trial processes, both companies aim to foster innovation and broaden access to critical research. This collaboration not only underscores Merck’s commitment to advancing cancer care but also sets a precedent for integrating sophisticated technology into pharmaceutical research and development.
